GAMMA Investing
PVLA icon

GAMMA Investing’s Palvella Therapeutics PVLA Stock Holding History

GAMMA Investing’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$14.1K Buy
102
+65
+176% +$9.64K ﹤0.01% 3159
2026
Q2 		$5.65K Buy
37
+9
+32% +$1.09K ﹤0.01% 3417
2026
Q1 		$3.49K Buy
28
+7
+33% +$730 ﹤0.01% 3499
2025
Q4 		$2.2K Buy
21
+4
+24% +$341 ﹤0.01% 3572
2025
Q3 		$1.07K Buy
+17
New +$758 ﹤0.01% 3600

Other funds holding PVLA

CAM
Clio Asset Management Charlottesville, Virginia $119M AUM 1.1% 1-Year Est. Return
Avior Wealth Management
Avior Wealth Management Omaha, Nebraska $3.79B AUM 15.36% 1-Year Est. Return
Eastern Bank
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
CoreCap Advisors
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return

GAMMA Investing's PVLA Position: Q3 2026 in Review

GAMMA Investing increased its Palvella Therapeutics (PVLA) stake by 176% in Q3 2026, buying an estimated $9.64K and bringing the position to 102 shares worth $14.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3159.

GAMMA Investing first reported a position in PVLA in Q3 2025 and has held it in 5 quarters since. 9 funds tracked by Wall St. Rank hold PVLA as of Q3 2026.

  • GAMMA Investing held 102 shares of Palvella Therapeutics worth $14.1K as of Q3 2026.
  • GAMMA Investing bought 65 Palvella Therapeutics shares in Q3 2026, an estimated $9.64K.
  • Palvella Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3159 holding.
  • GAMMA Investing first reported a position in Palvella Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • 9 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.